BR112016012141A2 - "combinações farmacêuticas, uso das mesmas, e embalagem comercial" - Google Patents
"combinações farmacêuticas, uso das mesmas, e embalagem comercial"Info
- Publication number
- BR112016012141A2 BR112016012141A2 BR112016012141A BR112016012141A BR112016012141A2 BR 112016012141 A2 BR112016012141 A2 BR 112016012141A2 BR 112016012141 A BR112016012141 A BR 112016012141A BR 112016012141 A BR112016012141 A BR 112016012141A BR 112016012141 A2 BR112016012141 A2 BR 112016012141A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- combination
- pharmaceutical
- commercial packaging
- pyridin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
COMBINAÇÕES FARMACÊUTICAS, USO DAS MESMAS, E EMBALAGEM COMERCIAL. A presente invenção refere-se a uma combinação farmacêutica contendo: (a) um inibidor de fosfatidilinositol-3-cinase selecionado entre 5-(2,6-di-morfolin-4-il-pirimidin-4-il)-4-trifluorometil-piridin-2-ilamina, 2-amida 1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il}-amida) de ácido (S)-Pirrolidina-1,2-dicarboxílico ou qualquer sal farmaceuticamente aceitável dos mesmos e (b) um agonista de gonadorelina e, opcionalmente, (c) um agente antiestrogênio, particularmente para uso no tratamento ou prevenção de um câncer; usos dessa combinação na preparação de um medicamento para o tratamento ou prevenção de um câncer; composições farmacêuticas da combinação dos referidos agentes terapêuticos e métodos de tratamento de um câncer em um paciente compreendendo administrar ao referido paciente um montante terapeuticamente eficaz dessa combinação.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14305057 | 2014-01-15 | ||
PCT/IB2015/050260 WO2015107461A1 (en) | 2014-01-15 | 2015-01-13 | Pharmaceutical combinations |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016012141A2 true BR112016012141A2 (pt) | 2017-08-08 |
Family
ID=50033443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016012141A BR112016012141A2 (pt) | 2014-01-15 | 2015-01-13 | "combinações farmacêuticas, uso das mesmas, e embalagem comercial" |
Country Status (11)
Country | Link |
---|---|
US (2) | US20160331755A1 (pt) |
EP (1) | EP3094340A1 (pt) |
JP (2) | JP2017502989A (pt) |
KR (1) | KR20160101027A (pt) |
CN (2) | CN112535688A (pt) |
AU (2) | AU2015207723A1 (pt) |
BR (1) | BR112016012141A2 (pt) |
CA (1) | CA2936783A1 (pt) |
MX (1) | MX2016009226A (pt) |
RU (2) | RU2020121929A (pt) |
WO (1) | WO2015107461A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3731842A1 (en) * | 2017-12-28 | 2020-11-04 | Constellation Pharmaceuticals, Inc. | Pharmacokinetic enhancement of ezh2 inhibitors through combination therapies |
WO2023150267A1 (en) * | 2022-02-03 | 2023-08-10 | Maison Amori Oqvpo Llc | Methods, compositions and uses for treating cancer by providing medications that induce targeted tumor cell mitosis before providing chemotherapy or radiation and kits therefor |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
MX2007008809A (es) * | 2005-01-21 | 2007-09-07 | Astex Therapeutics Ltd | Combinaciones de inhibidores de pirazol cinasa y otros agentes antitumor. |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
CN101019828A (zh) * | 2007-03-23 | 2007-08-22 | 济南帅华医药科技有限公司 | 一种含磷酸肌醇3-激酶抑制剂及激素类药物的抗癌组合物 |
CA2684932A1 (en) * | 2007-05-09 | 2008-11-20 | Novartis Ag | Substituted imidazopyridazines as pi3k lipid kinase inhibitors |
UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
AR081823A1 (es) * | 2010-04-14 | 2012-10-24 | Incyte Corp | DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd |
EP2592933B1 (en) * | 2010-07-16 | 2017-04-05 | Anderson Gaweco | Mif inhibitors and their uses |
BR112014004587A2 (pt) * | 2011-08-31 | 2017-03-14 | Novartis Ag | combinações sinérgicas de inibidores de pi3k- e de mek |
US20150023954A1 (en) * | 2012-03-23 | 2015-01-22 | Memorial Sloan-Kettering Cancer Center | Potentiating antibody-induced complement-mediated cytotoxicity via pi3k inhibition |
CA2931615A1 (en) * | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
-
2015
- 2015-01-13 US US15/109,704 patent/US20160331755A1/en not_active Abandoned
- 2015-01-13 WO PCT/IB2015/050260 patent/WO2015107461A1/en active Application Filing
- 2015-01-13 KR KR1020167018718A patent/KR20160101027A/ko active IP Right Grant
- 2015-01-13 JP JP2016546785A patent/JP2017502989A/ja not_active Withdrawn
- 2015-01-13 AU AU2015207723A patent/AU2015207723A1/en not_active Abandoned
- 2015-01-13 BR BR112016012141A patent/BR112016012141A2/pt not_active Application Discontinuation
- 2015-01-13 EP EP15701257.6A patent/EP3094340A1/en not_active Withdrawn
- 2015-01-13 CN CN202011428621.1A patent/CN112535688A/zh active Pending
- 2015-01-13 CA CA2936783A patent/CA2936783A1/en not_active Abandoned
- 2015-01-13 CN CN201580004798.XA patent/CN105916515A/zh active Pending
- 2015-01-13 MX MX2016009226A patent/MX2016009226A/es unknown
- 2015-01-13 RU RU2020121929A patent/RU2020121929A/ru unknown
- 2015-01-13 RU RU2016133285A patent/RU2016133285A/ru unknown
-
2017
- 2017-07-11 US US15/646,494 patent/US10085996B2/en not_active Expired - Fee Related
- 2017-10-10 AU AU2017245302A patent/AU2017245302B2/en not_active Ceased
-
2019
- 2019-09-13 JP JP2019167076A patent/JP2020023497A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20170304311A1 (en) | 2017-10-26 |
RU2020121929A (ru) | 2020-07-13 |
US20160331755A1 (en) | 2016-11-17 |
RU2016133285A (ru) | 2018-02-20 |
EP3094340A1 (en) | 2016-11-23 |
CN112535688A (zh) | 2021-03-23 |
JP2020023497A (ja) | 2020-02-13 |
AU2017245302A1 (en) | 2017-11-02 |
WO2015107461A1 (en) | 2015-07-23 |
CN105916515A (zh) | 2016-08-31 |
RU2016133285A3 (pt) | 2018-08-28 |
AU2015207723A1 (en) | 2016-06-09 |
JP2017502989A (ja) | 2017-01-26 |
CA2936783A1 (en) | 2015-07-23 |
AU2017245302B2 (en) | 2019-04-04 |
MX2016009226A (es) | 2016-10-05 |
US10085996B2 (en) | 2018-10-02 |
KR20160101027A (ko) | 2016-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015030578A2 (pt) | combinações farmacêuticas | |
CL2023000847A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
MX2019012884A (es) | Terapia de combinacion. | |
BR112017017009A2 (pt) | usos de um sequestrante de formaldeído e de uma composição farmacêutica, métodos para impedir, adiar, retardar ou diminuir a transformação de um composto e para tratar câncer, e, composição farmacêutica. | |
BR112014028633A8 (pt) | tratamento de amd usando sflt-1 de aav | |
MX2021000376A (es) | Composiciones tópicas para el alivio del dolor. | |
HRP20220718T1 (hr) | Kombinacijska terapija uključujući inhibitor mdm2 i jedan ili više dodatnih farmaceutski aktivnih sredstava za liječenje raka | |
MX2021001807A (es) | Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma. | |
BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
BR112015030664A2 (pt) | combinação farmacêutica de um inibidor de pi3k e um agente desestabilizador de microtúbulos | |
MX2014002471A (es) | Combinaciones sinergicas de los inhibidores de p13k y mek. | |
AR074313A1 (es) | Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo. uso. kit | |
AR088585A1 (es) | Un medicamento para tratar la enfermedad del ojo anterior | |
BR112015001212A2 (pt) | terapia de combinação de inibidores de igf1 r e pi3k | |
PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
WO2015035410A8 (en) | Cancer therapy | |
UY35890A (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
CL2011000805A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion de lictus en pacientes que padecen fibrilacion auricular. | |
EA201270747A1 (ru) | Композиции и способы для профилактики и лечения ран | |
BR112016012141A2 (pt) | "combinações farmacêuticas, uso das mesmas, e embalagem comercial" | |
MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
AR107935A1 (es) | Uso del compuesto 6-(4-(2,3-dimetilfenoxi)piperidin-1-il)metil)pirimidino-2,4(1h,3h)-diona o una sal farmacéuticamente aceptable del mismo para preparar un medicamento, combinación y composición farmacéutica que comprende dicho compuesto | |
CL2020001426A1 (es) | Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo. | |
BR112015012497A8 (pt) | combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |